<!DOCTYPE html>
<html lang="en">
<head>
  
  
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    
    <link rel="canonical" href="https://jzpero.github.io/mednotes/Infectious%20Diseases/Infective%20Endocarditis/">
    <link rel="shortcut icon" href="../../img/favicon.ico">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
    <title>Infective Endocarditis - MedNotes</title>
    <link href="../../css/bootstrap-3.3.7.min.css" rel="stylesheet">
    <link href="../../css/font-awesome-4.7.0.css" rel="stylesheet">
    <link href="../../css/base.css" rel="stylesheet">
    <link rel="stylesheet" href="../../css/highlight.css">
    <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <script src="../../js/jquery-3.2.1.min.js"></script>
    <script src="../../js/bootstrap-3.3.7.min.js"></script>
    <script src="../../js/highlight.pack.js"></script>
    
    <base target="_top">
    <script>
      var base_url = '../..';
      var is_top_frame = false;
        
        var pageToc = [
          {title: "Infective Endocarditis", url: "#_top", children: [
          ]},
          {title: "Definitions \u0026amp; Background", url: "#definitions-background", children: [
          ]},
          {title: "Clinical Manifestations", url: "#clinical-manifestations", children: [
              {title: "Tempo of Disease", url: "#tempo-of-disease" },
              {title: "Clinical Manifestations", url: "#clinical-manifestations_1" },
              {title: "Duke Criteria", url: "#duke-criteria" },
          ]},
          {title: "Workup", url: "#workup", children: [
          ]},
          {title: "Management", url: "#management", children: [
              {title: "Medical Treatment", url: "#medical-treatment" },
              {title: "Surgical Considerations (per 2021 AHA/ACC Guidelines)", url: "#surgical-considerations-per-2021-ahaacc-guidelines" },
          ]},
          {title: "Prophylaxis", url: "#prophylaxis", children: [
          ]},
          {title: "References \u0026amp; Resources", url: "#references-resources", children: [
          ]},
        ];

    </script>
    <script src="../../js/base.js"></script> 
</head>

<body>
<script>
if (is_top_frame) { $('body').addClass('wm-top-page'); }
</script>



<div class="container-fluid wm-page-content">
  <a name="_top"></a>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Legionella%20Infection/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Legionella%20Infection/" class="btn btn-xs btn-link">
        Legionella Infection
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Hypervirulent%20Klebsiella%20pneumoniae/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Hypervirulent%20Klebsiella%20pneumoniae/" class="btn btn-xs btn-link">
        Hypervirulent Klebsiella pneumoniae
      </a>
    </div>
    
  </div>

    

    <h1 id="infective-endocarditis">Infective Endocarditis</h1>
<h1 id="definitions-background">Definitions &amp; Background</h1>
<p>Bacterial vegetations comprised of platelets, fibrin, microorganisms, and inflammatory cells generally involve the heart valves and intracardiac devices.</p>
<p><strong>Endothelial injury</strong> allows for either direct infection or formation of a nonbacterial thrombotic endocarditis (NBTE) which can become infected during transient bacteremia. More virulent bugs tend to adhere directly to the endothelium. Other bugs tend to adhere to the NBTE. Risk factors for NBTE are valvular defects (MR, AS, AR), VSD, CHD, hypercoagulable states (marantic endocarditis), SLE, and antiphospholipid syndrome.</p>
<p>Organisms deep within the vegetation are metabolically inactive and difficult to eradicate. Embolization of vegetation fragments can lead to distant infection or infarction. Intracardiac structures can be damaged (perivalvular abscesses, conduction blocks), and tissue damage arises from immune complex deposition or responses to deposited bacterial antigens.</p>
<p><strong>Risk factors</strong> are fairly obvious:</p>
<ul>
<li>congenital heart diseases</li>
<li>chronic rheumatic heart disease</li>
<li>IV drug use</li>
<li>degenerative valves</li>
<li>intracardiac devices (<a href="../../Cardiology/Arrhythmias/ICD%20Therapy/">ICD</a>, pacemaker, etc)</li>
<li>old age</li>
<li>prosthetic valves</li>
<li>bioprosthetics and mechanicals have similar risk profiles</li>
<li>risk is greatest in the first 6 to 12 mo</li>
<li>risk declines to a low, stable level after</li>
</ul>
<p><strong>Causative organisms</strong> are typically bacteria, but can be fungal as well.</p>
<table>
  <thead>
    <tr>
      <th style="text-align:left">Organism</th>
      <th style="text-align:left">Associations</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align:left">viridans <em>Streptococci</em>
      </td>
      <td style="text-align:left">dental procedures</td>
    </tr>
    <tr>
      <td style="text-align:left">HACEK group</td>
      <td style="text-align:left">upper respiratory tract</td>
    </tr>
    <tr>
      <td style="text-align:left">CoNS</td>
      <td style="text-align:left">
        <ul>
          <li>skin</li>
          <li>implantable devices</li>
        </ul>
      </td>
    </tr>
    <tr>
      <td style="text-align:left"><em>Streptococcus gallolyticus (bovis)</em>
      </td>
      <td style="text-align:left">colon cancer</td>
    </tr>
    <tr>
      <td style="text-align:left"><em>Enterococcus</em> spp.</td>
      <td style="text-align:left">genitourinary tract</td>
    </tr>
    <tr>
      <td style="text-align:left"><em>Staphylococcus aureus</em>
      </td>
      <td style="text-align:left">
        <ul>
          <li>IV drug use (tricuspid)</li>
          <li>implantable devices</li>
          <li>healthcare-associated</li>
        </ul>
      </td>
    </tr>
  </tbody>
</table>

<p>Breakdowns of common bugs varies by population and valve replacement status, but <em>Streptococci</em> and <em>Staph aureus</em> are by far the two most common.</p>
<p>Some conditions can mimic infectious endocarditis:</p>
<ul>
<li>atrial myxoma</li>
<li>marantic endocarditis</li>
<li>antiphospholipid syndrome/lupus (Libman-Sacks endocarditis)</li>
</ul>
<h1 id="clinical-manifestations">Clinical Manifestations</h1>
<h2 id="tempo-of-disease">Tempo of Disease</h2>
<p>The <strong>time-course and aggression</strong> of disease is dictated by the causative organism.</p>
<ul>
<li><strong>Acute endocarditis</strong> is a febrile and aggressive disease. It causes rapid damage to cardiac structures, seeds extracardiac sites, and causes death within weeks of untreated.</li>
<li>beta-hemolytic strep, Staph aureus, pneumococci</li>
<li><strong>Subacute endocarditis</strong> has a more indolent course. It causes slow progressive damage and rarely metastasizes unless there is a major embolic event or rupture of a mycotic aneurysm.</li>
<li>viridans Strep, CoNS, HACEK, Bartonella, Whipple's disease, Staph aureus</li>
</ul>
<h2 id="clinical-manifestations_1">Clinical Manifestations</h2>
<table>
<thead>
<tr>
<th>System</th>
<th>Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic</td>
<td>fevers, weight loss, constitutional symptoms</td>
</tr>
<tr>
<td>Cardiac</td>
<td>new regurgitant murmurs, heart failure, perivalvular abscess, heart block, coronary embolism</td>
</tr>
<tr>
<td>Extracardiac</td>
<td>Janeway lesions (immune), Osler nodes and splinter hemorrhages (vascular), MSK pain, distal embolization, stroke, glomerulonephritis</td>
</tr>
</tbody>
</table>
<h2 id="duke-criteria">Duke Criteria</h2>
<p>The <strong>Duke Criteria</strong> are a highly sensitive and specific set of clinical, laboratory, and echocardiographic findings of infective endocarditis. It emphasizes bacteremia and echocardiography. To satisfy the criteria, you must have one of the following combinations:</p>
<p><img alt="" src="../_attachments/Pasted%20image%2020230126192154.png" /></p>
<h1 id="workup">Workup</h1>
<ol>
<li><strong>Blood cultures</strong> - at least 2 sets prior to antibiotics. Consider obtaining 3 two-bottle sets, separated by 2+ hours, if no antibiotics have been received within the past two weeks. <em>5 to 15% of cases have negative blood cultures</em>, and much of this is due to either prior antibiotic exposure or fastidious organisms.</li>
<li><strong>Serology</strong> can be drawn for <em>Brucella, Bartonella, <a href="../Legionella%20Infection/">Legionella</a>, Chlamydia psittaci, and Coxiella burnetti</em>, if you think these are likely.</li>
<li><strong>Start with an initial TTE for all patients.</strong></li>
<li><strong>Consider TEE</strong> if TTE nondiagnostic, IE complications suspected, or there are intracardiac leads. (Class I indications). Extremely specific, but cannot image vegetations less than 2 mm diameter. False negative rate is 6 to 18% in initial imaging, and so likely endocarditis may require a second TEE in 7 to 10 days if the first TEE is negative.<ol>
<li><em><strong>Staphylococcus aureus</strong></em> <strong>bacteremia is an indication for routine TEE</strong>, due to the high prevalence of infective endocarditis with this bug.</li>
</ol>
</li>
<li><strong>Other imaging</strong> is less common, and may involve 3D TEE or FGD-PET/CT.</li>
</ol>
<h1 id="management">Management</h1>
<h2 id="medical-treatment">Medical Treatment</h2>
<p><img alt="" src="../_attachments/Pasted%20image%2020230126192650.png" />
See <a href="../Enterococcal%20Bacteremia/">Enterococcal Bacteremia</a> for more specific information on Enterococcal endocarditis. See <a href="../Staph%20Aureus%20Bacteremia/">Staph Aureus Bacteremia</a> for more information for SA associated endocarditis.</p>
<h3 id="de-escalation-to-oral-therapy">De-Escalation to Oral Therapy</h3>
<p>The <strong>POET (NEJM 2019) trial</strong> compared partial PO vs IV antibiotic therapy for IE. 400 adults with IE (SA, E faecalis, CoNS) randomized to full IV therapy vs transition to PO after &gt;10 days of IV. No difference in the primary outcome of mortality/cardiac surgery/embolism/bacteremia relapse within 6 months between the two groups. <em>However, patients were followed 3x weekly, all had TEE, mostly L sided IE, and very few IVDU.</em></p>
<div class="admonition note">
<p class="admonition-title">POET (2019)</p>
<p>In select patients with left sided IE (Strep, E faecalis, S aureus, CNST) who are stable, consider transition to PO antibiotics after at least 10 days of IV therapy. Requires:</p>
<ol>
<li>TEE before the switch to PO to demonstrate no paravalvular infection</li>
<li>Frequent and close followup</li>
<li>Followup TEE 1-3 days before the completion of the antibiotic course.</li>
</ol>
</div>
<h2 id="surgical-considerations-per-2021-ahaacc-guidelines">Surgical Considerations (per 2021 AHA/ACC Guidelines)</h2>
<h3 id="class-i-indications">Class I Indications</h3>
<p><img alt="" src="../_attachments/Pasted%20image%2020230126193240.png" />
<img alt="" src="../_attachments/Pasted%20image%2020230126192526.png" /></p>
<h3 id="class-ii-indications">Class II Indications</h3>
<p><img alt="" src="../_attachments/Pasted%20image%2020230126192540.png" /></p>
<h1 id="prophylaxis">Prophylaxis</h1>
<p><img alt="" src="../_attachments/Pasted%20image%2020230126193536.png" /></p>
<h1 id="references-resources">References &amp; Resources</h1>
<ol>
<li>Harrison's Principles of Internal Medicine, 20e</li>
<li>Lilly Pathophysiology of Heart Disease</li>
<li><a href="https://www.nejm.org/doi/full/10.1056/NEJMcp1206782">Hoen B and Duval X. Infective Endocarditis. New Eng J Med. 2013; 368:1425-33.</a></li>
<li>2021 IM Review Slides</li>
</ol>

  <br>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Legionella%20Infection/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Legionella%20Infection/" class="btn btn-xs btn-link">
        Legionella Infection
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Hypervirulent%20Klebsiella%20pneumoniae/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Hypervirulent%20Klebsiella%20pneumoniae/" class="btn btn-xs btn-link">
        Hypervirulent Klebsiella pneumoniae
      </a>
    </div>
    
  </div>

    <br>
</div>

<footer class="container-fluid wm-page-content">
  <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a> using <a href="https://github.com/gristlabs/mkdocs-windmill">Windmill</a> theme by Grist Labs.</p>
</footer>

</body>
</html>